Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on August 12, 2021, by Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation trading on the NASDAQ Capital Market. The filing serves to announce the company's financial results for the period ended June 30, 2021.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references a press release (Exhibit 99.1) for the detailed financial data but does not include the figures within the 8-K document itself.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2021, by reviewing the press release attached as Exhibit 99.1.
- Confirm the company's cash position and runway, as these metrics are not disclosed in the 8-K text.
- Note that the financial data referenced in this filing is not legally "filed" under Section 18 of the Exchange Act.
- Check for any subsequent filings that may incorporate the referenced press release by reference.